

17 January 2023

**Intuitive Investments Group plc**

("IIG" or the "Company")

**Result of Annual General Meeting and Directorate Change**

Intuitive Investments Group plc (AIM: IIG), a closed-end investment company focussed on the life sciences sector, announces that at the Annual General Meeting held today, all resolutions were duly passed.

The results of the proxy voting are summarised in the table below:

Resolution	Votes For	Votes Against	Withheld
One	30,133,533	0	0
Two	30,133,533	0	0
Three	30,133,533	0	0
Four	30,133,533	0	0
Five	30,133,533	0	0
Six	30,133,533	0	0
Seven	30,133,533	0	0
Eight	30,133,533	0	0

IIG also announces that Dr Cormac Kilty, Independent Non-Executive Director, has informed the Board of his intention to step down at the end of this month. Given the size of the Company, where the Board, further to Cormac's retirement, will consist of three independent non-executive and one executive director, a replacement is not being sought.

**Julian Baines, Chairman of IIG, commented:**

*"On behalf of everyone at IIG, I would like to thank Cormac for his service at IIG as a non-executive director, particularly his hard work at the time of flotation and his subsequent input into the Company's investments. He will be sorely missed at Board meetings."*

**For further information, please contact:**

**Intuitive Investments Group plc**

Julian Baines, Chairman  
Robert Naylor, CEO

[www.iigplc.com](http://www.iigplc.com)

Via Walbrook PR

**SP Angel Corporate Finance LLP - Nominated Adviser**

Jeff Keating / David Hignell / Kasia Brzozowska

+44 (0) 20 3470 0470

**Turner Pope Investments (TPI) Ltd - Broker**

Andrew Thacker / James Pope

+44 (0) 20 3657 0050

**Walbrook PR Limited - Media & Investor Relations**

+44 (0)20 7933 8780 or [intuitive@walbrookpr.com](mailto:intuitive@walbrookpr.com)

Paul McManus / Sam Allen

+44 (0) 7980 541 893 / +44 (0) 7502 558 258

**About Intuitive Investments Group plc**

Intuitive Investments Group plc is an investment company seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman of the Investment Committee, David Evans, to seek to generate capital growth over the long term for shareholders